performed a phase I/II trial to evaluate whether the HDAC inhibitor, vorinostat, could reduce the incidence of GVHD if administered 10 days before transplantation until day 100 in patients with high-risk hematological malignant disease who received stem cell grafts from matched related donors after reduced intensity conditioning (121). This evidence concerns the gene HDAC9 and graft versus host disease.